Greenwich LifeSciences, Inc. GLSI
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
Greenwich LifeSciences, Inc. (GLSI) is a healthcare company listed in the US with a market value of about $219M.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -1211%.
About Greenwich LifeSciences
Greenwich LifeSciences is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2020. It was profitable in 0 of the last 7 years in our data. Its share count rose by 5% over three years (dilution for shareholders).
Score: 0.6 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Net income | -$19M | -$17M | -$9M | -$8M | -$5M | -$2M | -$3M |
| Free cash flow | -$10M | — | — | — | — | — | -$293267 |
| EPS (diluted) | $-1.43 | $-1.34 | $-0.69 | $-0.61 | $-0.35 | $-0.20 | $-1.52 |
| Net margin | — | — | — | — | — | — | — |
| ROIC | -4349.7% | -1533.5% | -110.0% | -48.1% | -13.5% | -5.3% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $57.00, 282% above the current price; targets range from $45.00 to $69.00; the consensus rating is “none”; expected EPS is $-1.39 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Greenwich LifeSciences pay a dividend?
Not currently.
Is Greenwich LifeSciences a good stock to buy?
We do not give buy or sell advice. Greenwich LifeSciences scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.